Trials / Completed
CompletedNCT01099540
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | Pazopanib 800 mg qd daily |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-03-01
- Completion
- 2013-03-01
- First posted
- 2010-04-07
- Last updated
- 2015-12-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01099540. Inclusion in this directory is not an endorsement.